REGENXBIO (NASDAQ:RGNX) Reaches New 12-Month Low at $26.78

REGENXBIO Inc. (NASDAQ:RGNX) reached a new 52-week low on Thursday . The stock traded as low as $26.78 and last traded at $26.95, with a volume of 679716 shares trading hands. The stock had previously closed at $28.67.

Several equities research analysts recently weighed in on RGNX shares. Chardan Capital dropped their price target on REGENXBIO from $100.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, November 3rd. Zacks Investment Research lowered REGENXBIO from a “hold” rating to a “sell” rating in a research report on Thursday, January 6th. SVB Leerink dropped their price target on REGENXBIO from $44.00 to $43.00 and set a “market perform” rating on the stock in a research report on Wednesday, November 3rd. Wedbush started coverage on REGENXBIO in a research report on Wednesday, December 15th. They set a “neutral” rating and a $29.00 price target on the stock. Finally, Roth Capital boosted their target price on REGENXBIO from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, October 25th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, REGENXBIO presently has a consensus rating of “Hold” and a consensus price target of $52.25.

The stock has a market capitalization of $1.20 billion, a P/E ratio of -5.41 and a beta of 0.92. The business has a fifty day moving average price of $32.38 and a 200-day moving average price of $34.72.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings results on Tuesday, November 2nd. The biotechnology company reported ($1.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.50). The business had revenue of $30.77 million for the quarter, compared to the consensus estimate of $49.35 million. REGENXBIO had a negative net margin of 228.08% and a negative return on equity of 44.70%. During the same period in the previous year, the company earned $0.23 earnings per share. As a group, research analysts anticipate that REGENXBIO Inc. will post 1.5 earnings per share for the current year.

In related news, CEO Kenneth T. Mills sold 1,500 shares of the company’s stock in a transaction on Monday, November 8th. The stock was sold at an average price of $40.00, for a total transaction of $60,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Steve Pakola sold 1,598 shares of the company’s stock in a transaction on Monday, January 3rd. The shares were sold at an average price of $33.75, for a total value of $53,932.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 64,736 shares of company stock worth $2,234,280. Corporate insiders own 12.40% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the stock. Comerica Bank increased its position in REGENXBIO by 3.4% during the third quarter. Comerica Bank now owns 32,298 shares of the biotechnology company’s stock valued at $1,167,000 after acquiring an additional 1,072 shares during the last quarter. Bank of New York Mellon Corp increased its position in REGENXBIO by 5.9% in the third quarter. Bank of New York Mellon Corp now owns 338,873 shares of the biotechnology company’s stock worth $14,206,000 after buying an additional 18,869 shares in the last quarter. BNP Paribas Arbitrage SA increased its position in REGENXBIO by 202.2% in the third quarter. BNP Paribas Arbitrage SA now owns 37,613 shares of the biotechnology company’s stock worth $1,577,000 after buying an additional 25,167 shares in the last quarter. Squarepoint Ops LLC increased its position in REGENXBIO by 75.4% in the third quarter. Squarepoint Ops LLC now owns 47,605 shares of the biotechnology company’s stock worth $1,996,000 after buying an additional 20,463 shares in the last quarter. Finally, Thrivent Financial for Lutherans increased its position in REGENXBIO by 6.3% in the third quarter. Thrivent Financial for Lutherans now owns 30,303 shares of the biotechnology company’s stock worth $1,270,000 after buying an additional 1,807 shares in the last quarter. Institutional investors own 78.46% of the company’s stock.

About REGENXBIO (NASDAQ:RGNX)

REGENXBIO, Inc is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors; and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381.

See Also: Why Dividend Stocks May Be Right for You

Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.